唑来膦酸联合酮康唑及强的松治疗晚期去势抵抗性前列腺癌骨转移

Treatment for Patients with Advanced Metastatic Castration Resistant Prostate Cancer by Using Zoledronic Acid Combined with Ketoconazole and Prednisone

目的:探讨唑来膦酸联合酮康唑及强的松治疗晚期去势抵抗性前列腺癌骨转移的疗效。方法:23例晚期去势抵抗性前列腺癌骨转移患者采用唑来膦酸联合酮康唑及强的松治疗,观察PSA变化情况,骨痛缓解程度。结果:PSA下降13例,总有效率56.52%,PSA下降中位有效时间7.38个月。止痛疗效,显效13例(56.52%),中位时间7.53个月;有效8例(34.78%),中位时间5.53个月;无效2例(8.70%)。所有患者均未出现明显不良反应。结论:唑来膦酸联合酮康唑及强的松治疗晚期去势抵抗性前列腺癌骨转移,能有效减轻患者尿路症状,有效缓解骨痛,减少不良事件发生,提高患者生活质量,延长患者生存时间。

Objective： To evaluate the effect of Znledronie Acid combined with Ketoconazole and Prednisone in the treatment of advanced metastatic castration resistant prostate cancer（mCRPC）.Method： 23 patients with advanced mCRPC were treated with Zeledronic Acid combined with Ketoeonazole and Prednisone, PSA changes and degree of bone pain relieving were observed.Result： PSA decreasing occured in 13 eases（56.52%）, the median effective time of PSA decreasing was 7.38 months.The significant efficiency of bone pain relieving occurred in 13 cases（56.52%）, the median time was 7.53 months.The effective efficiency occurred in 8 cases（34.78%）, the median effective time of PSA decreasing was 7.38 months.The inefficiency occurred in 2 cases（8.70%）.No apparent side effect oceuured in our study.Conclusion： The treatment for patients with advanced mCRPC with Zoledronie Acid combined with Ketoconazole and Prednisone can effectively relieve their urinary tract symptoms and bone pain, decrease generation of adverse bone events, inhance life quality and prolong survival time.